BioNTech Results Presentation Deck

Oncology Pipeline: 15 Product Candidates in 19 Ongoing Clinical Trials Drug class mRNA Antibodies SMIM ³ 38 Platform Fix Vac (fixed combination of shared cancer antigens) iNeST (patient specific cancer antigen therapy) Intratumoral Immunotherapy RiboCytokines (mRNA-encoded Cytokines) Next-Gen CP² Immunomodulators Targeted Cancer Antibodies Toll-Like Receptor Binding CAR-T Cells Cell Therapies Neoantigen-based T cell therapy Product Candidate BNT111 BNT112 BNT113 BNT115 autogene cevumeran (BNT122) SAR441000 (BNT131) BNT151 BNT152 + BNT153 GEN1046 (BNT311) GEN1042 (BNT312) BNT321 (MVT-5873) BNT411 BNT211 BNT221 (NEO-PTC-01) Indication (Targets) advanced melanoma prostate cancer HPV16+ head and neck cancer¹ ovarian cancer¹ 1L melanoma adjuvant colorectal cancer solid tumors solid tumors (IL-12sc, IL-15sushi, GM-CSF, IFN a) solid tumors (optimized IL-2) solid tumors (IL-7, IL-2) solid tumors (PD-L1x4-1BB) solid tumors (CD40x4-1BB) pancreatic cancer (sLea) solid tumors (TLR7) solid tumors (CLDN6) solid tumors Preclinical Phase 1 ¹BNT113 and BNT115 are currently being studied in investigator-initiated Phase 1 trials. 2Checkpoint Inhibitor. ³Small Molecule Immunomodulators. Phase 2 Phase 3 Rights Collaborator fully-owned fully-owned fully-owned fully-owned Genentech (global 50:50 profit/loss) Sanofi (global profit/loss share) fully-owned fully-owned Genmab (global 50:50 profit/loss) fully-owned fully-owned fully-owned fully-owned BIONTECH

View entire presentation